Five-year follow-up of ustekinumab efficacy: the influence of dose modification

Affiliations

Comment

A D Ormerod. Br J Dermatol. 2015 May.

. 2015 May;172(5):1193-4.

doi: 10.1111/bjd.13735.

¹ Division of Applied Medicine, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, U.K.. a.d.ormerod@abdn.ac.uk.

No abstract available

Comment on

Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up.
Langley RG, Lebwohl M, Krueger GG, Szapary PO, Wasfi Y, Chan D, Hsu MC, You Y, Poulin Y, Korman N, Prinz JC, Reich K; PHOENIX 2 Investigators. Langley RG, et al. Br J Dermatol. 2015;172(5):1371-83. doi: 10.1111/bjd.13469. Epub 2015 Mar 22. Br J Dermatol. 2015. PMID: 25307931 Clinical Trial.